COMMUNIQUÉS West-GlobeNewswire

Gritstone bio Announces Workforce Reduction
29/02/2024
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% [...]
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
29/02/2024
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant ( [...]
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
29/02/2024
– Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively – – Long-term data from Phase 2b ENLIVEN trial [...]
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
29/02/2024
Record DANYELZA® net product revenues of $ 23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42 % and 71%, respectively Cash and cash equivalents of $ 78.6 million as of December 31, 2023; [...]
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
29/02/2024
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29/02/2024
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in [...]
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29/02/2024
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C [...]
Nextech to Unveil Patient Journey Innovations Driven by AI for Specialty Practices at 10th Annual EDGE User Conference
29/02/2024
TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Nextech, a leading provider of clinical and administrative healthcare technology solutions for specialty physician practices, today announced clients will be the first to [...]
Opération de regroupement d'actions
29/02/2024
Communiqué de presse Ecully, le 29 février 2024 – 18h Prise d’effet du regroupement des actions Spineway Spineway annonce la finalisation de l’opération de regroupement de ses actions par échange de 1 action nouvelle de [...]
Reverse stock split
29/02/2024
Press release Ecully, February 29, 2024 – 6:00 p.m. Effective date of the Spineway reverse stock split Spineway announces the completion of the reverse stock split by exchanging 1 new share of 4.00 euros par value for 2 [...]
NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2024
29/02/2024
Company announcement no. 3 – 24 29 February 2024 NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2024 The Annual General Meeting of NTG Nordic Transport Group A/S will be held on Thursday, [...]
Health Advocate Applauds Federal Government in Free Access to Contraceptives for Canadians
29/02/2024
OTTAWA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologist of Canada (SOGC) applauds the Canadian government on today’s historic announcement to include free access for prescription [...]
Les professionnels de la santé applaudissent le gouvernement fédéral pour l'accès gratuit aux contraceptifs pour les Canadiens
29/02/2024
OTTAWA, 29 févr. 2024 (GLOBE NEWSWIRE) -- La Société des obstétriciens et gynécologues du Canada (SOGC) applaudit l’annonce historique du gouvernement canadien visant à inclure l'accès gratuit aux méthodes [...]
NTG Nordic Transport Group Annual Report for 2023
29/02/2024
Company announcement no. 2 – 24 29 February 2024 NTG Nordic Transport Group Annual Report for 2023 NTG Nordic Transport Group A/S (“NTG”) has today published the 2023 annual report. Selected financial highlights are [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
29/02/2024
Company Announcement COPENHAGEN, Denmark; February 29, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
DAS Health Expands Reach to Senior Living Organizations with Recent Acquisition
29/02/2024
Tampa, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- DAS Health, a provider of healthcare IT and business solutions, proudly announces the acquisition of Agility Holdings, LLC d/b/a vcpi. This significant acquisition expands [...]
Synaptive Medical Welcomes Chris Marrus as New Chief Commercial Officer
29/02/2024
New position of Chief Commercial Officer established to drive sales and growth for Synaptive Chris Marrus brings extensive experience in innovative med tech to Synaptive having held senior leadership roles at INSIGHTEC [...]
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
29/02/2024
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells [...]
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29/02/2024
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic [...]

Pages